---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000079"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:26:40.936593+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allogene appoints Geoffrey Parker as CFO effective Oct 16, 2023

## Summary
- Geoffrey Parker named EVP, CFO, Principal Financial & Accounting Officer, effective Oct 16, 2023.
- Previously COO/CFO at Tricida, CFO at Anacor (sold to Pfizer for $5.2B), MD at Goldman Sachs.
- Receives $490k base salary, 45% target bonus pro-rated for 2023, option for 950k shares, 400k RSUs.
- Also eligible for performance RSUs of 390k shares tied to $18 stock price or first FDA approval by 2028.
- Severance under CIC Plan: 18 months salary on change-in-control termination; 12 months on involuntary termination.

## SEC filing metadata
- accession: 0001737287-23-000079
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000079/0001737287-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000079/allo-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000079
- JSON: https://secwatch.observer/filing/0001737287-23-000079.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000079.txt

## Key facts
- Executive change
  Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
  source text: The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000079/0001737287-23-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.